Members of the board of directors

Hans Schikan, PharmD, Independent Director, Chairman of the Board

Dr Mark Vaeck, Chief Executive Officer

Dr Yvonne McGrath, Chief Scientific Officer

Gaston Matthyssens PhD, Managing Partner with Vesalius Biocapital

Veronique Vermeeren PhD, Investment Manager with LRM

Patrick Van Beneden, Partner with Gimv

Gilles Nobecourt, Partner with Andera Partners

Thierry Hercend, MD, PhD, Venture Partner with Andera Partners

Complix Cell Penetrating Alphabodies

A new revolutionary class of therapeutics targeting oncogenic intracellular targets